ArticleNature cancer2023
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02632071 (Multi-center Phase IB Trial of ACY-1215), which is not on this map. Cited by 41 papers.
0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer
Who cites it
41 citing papers in PubMed, 71 citations in OpenAlex.
- Article
- Post-translational modifications in metabolic reprogramming: implications for metabolic therapy and immunotherapy in cancer.Signal transduction and targeted therapy · 2026Review
- Prognostic, diagnostic and therapeutic value of the cancer tubulin code.Cancer metastasis reviews · 2026Review
- ACY-1215 ameliorates experimental colitis by inhibiting dendritic cell maturation and Th1/Th17 responses.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Protein modification systems as cancer biomarkers and therapeutic targets.Precision clinical medicine · 2026Review
- Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.Nature genetics · 2026Article
- Steroidogenic Acute Regulatory Protein in Breast Cancer: Mechanistic Insights into Pathogenesis and Therapeutics.International journal of molecular sciences · 2026Review
- GREmLN: A Cellular Graph Structure Aware Transcriptomics Foundation Model.bioRxiv : the preprint server for biology · 2026Article
- Calcium Dysregulation Promotes Glioma Progression by Inhibiting STAT3 Degradation Through Blocking Chaperone-Mediated Autophagy.Journal of cellular and molecular medicine · 2026Article
- Single-cell protein activity analysis reveals aberrant myogenesis and IGF2-PI3K pathway dependencies inScience advances · 2026Article
- HDAC5 deficiency induces intrinsic resistance to KRAS inhibition by disrupting c-Myc acetylation-ubiquitination homeostasis.The Journal of clinical investigation · 2026Article
- HDACi induces apoptosis of osteosarcoma cells by inhibiting the MAPK pathway.Scientific reports · 2026Article
- Sodium butyrate inhibits colorectal cancer development by reducing M2 macrophage polarization and PD-L1 expression.mSystems · 2025Article
- The Leupaxin/HDAC6/EGR2 axis facilitates breast cancer progression by enhancing macrophage M2 polarization.Cell biology and toxicology · 2025Article
- Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications.Molecular biomedicine · 2025Review
- Histone deacetylase 6: A new player in oxidative stress‑associated disorders and cancers (Review).International journal of molecular medicine · 2025Review
- Systematic identification and targeting of master regulator checkpoints (MRC) governing tumor microenvironment-mediated immune evasion.Journal for immunotherapy of cancer · 2025Review
- Histone Deacetylase 6 (HDAC6) in Ciliopathies: Emerging Insights and Therapeutic Implications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Identification and targeting of regulators of SARS-CoV-2-host interactions in the airway epithelium.Science advances · 2025Article
- Histone acetylation modulators in breast cancer.Breast cancer research : BCR · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
26 authors at 7 institutions in 1 country.
Tizita Z Zeleke *Graduate School, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Qingfei Pan *Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Codruta ChiuzanFeinstein Institutes for Medical Research, Northwell Health, New York, USA.ORCID http://orcid.org/0000-0001-8169-5032
Maika OnishiGenentech, South San Francisco, CA, USA.
Yuxin LiDepartments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-9739-9860
Haiyan TanCenter for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Mariano J AlvarezDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.
Erin HonanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Min YangAcetylon Pharmaceuticals, Boston, MA, USA.
Pei Ling ChiaGraduate School, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Partha MukhopadhyayGraduate School, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA.
Sean KellyDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Ruby WuDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Kathleen FennDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Meghna S TrivediDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Melissa AccordinoDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-4156-7279
Katherine D CrewDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Dawn L HershmanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA.
Matthew MaurerBristol-Myers Squibb, Princeton, NJ, USA.
Simon JonesRegenacy Pharmaceuticals, Inc., Waltham, MA, USA.
Anthony HighCenter for Proteomics and Metabolomics, St. Jude Children's Research Hospital, Memphis, TN, USA.
Junmin PengDepartments of Structural Biology and Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID http://orcid.org/0000-0003-0472-7648
Andrea CalifanoDepartment of Systems Biology, Columbia University Irving Medical Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4742-3679
Kevin Kalinsky *Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA. kevin.michael.kalinsky@emory.edu.ORCID http://orcid.org/0000-0002-3113-7902
Jiyang Yu *Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. jiyang.yu@stjude.org.ORCID http://orcid.org/0000-0003-3629-4330
Jose Silva *Department of Pathology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA. jose.silva@mssm.edu.ORCID http://orcid.org/0000-0001-5147-8950
Emory University · USSt. Jude Children's Research Hospital · USMount Sinai Hospital · USColumbia University Irving Medical Center · USAcetylon Pharmaceuticals (United States) · USBristol-Myers Squibb (United States) · USNorthwell Health · US
Funding
Systematic Identification and Pharmacological Targeting of Tumor Dependencies for Precision Cancer MedicineU01CA217858 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2017 to 2021
$6.1MElucidating and Targeting tumor dependencies and drug resistance determinants at the single cell levelU01CA272610 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2022 to 2026
$4.8MInvestigating the molecular mechanism that mediates the addiction of inflammatory breast cancer cells to HDAC6 functionR01CA201162 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SILVA, JOSE M · 2016 to 2020
$2.2MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MIntracellular and Intercellular Network Rewiring and Hidden Driver Inference from Single-Cell DataR01GM134382 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YU, JIYANG · 2019 to 2023
$1.7MNon-cancer gene addition as anticancer strategyR01CA153233 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SILVA, JOSE M · 2010 to 2012
$786kStorage System for High Performance ComputingS10OD021764 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2016 to 2016
$600kNCI NIH HHS R01 CA153233NCI NIH HHS R01 CA201162NCI NIH HHS U01 CA217858NCI NIH HHS U01 CA272610NIGMS NIH HHS R01 GM134382NIH HHS S10 OD012351NIH HHS S10 OD021764ODCDC CDC HHS S10 OD012351ODCDC CDC HHS S10 OD021764
Abstract
Inhibiting individual histone deacetylase (HDAC) is emerging as well-tolerated anticancer strategy compared with pan-HDAC inhibitors. Through preclinical studies, we demonstrated that the sensitivity to the leading HDAC6 inhibitor (HDAC6i) ricolinstat can be predicted by a computational network-based algorithm (HDAC6 score). Analysis of ~3,000 human breast cancers (BCs) showed that ~30% of them could benefice from HDAC6i therapy. Thus, we designed a phase 1b dose-escalation clinical trial to evaluate the activity of ricolinostat plus nab-paclitaxel in patients with metastatic BC (MBC) (NCT02632071). Study results showed that the two agents can be safely combined, that clinical activity is identified in patients with HR
Indexed as
Breast NeoplasmsFemaleHistone Deacetylase 6Histone DeacetylasesHumansHydroxamic AcidsPyrimidinesHDAC6 protein, humanHistone Deacetylase 6Histone DeacetylasesHydroxamic AcidsPyrimidinesricolinostat
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02632071ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.